In this phase, we analyzed 50 cases including 2 (4%) HGBCL-NOS, 8 (16%) high-grade B-cell lymphoma with MYC and BLC2/BCL6 rearrangement (HGBCL with MYC-BLC2/BCL6 R), 31 (62%) DLBCL-NOS, 7 (14%) tDLBCL (6 from follicular lymphoma-FL; 1 from marginal zone lymphoma, MZL), 1 (2%) BL and 1 (2%) HGBCL/LBCL-11q. This evidence concerns the gene MYC and marginal zone lymphoma.